{"entity":{"id":"ino-5401","kind":"drug","name":"INO-5401","aka":[],"tldr":"INO-5401 is an experimental cancer vaccine from Inovio Pharmaceuticals in phase 2 trials for glioma & glioblastoma, aimed at PSMA.","summary":"INO-5401 is a cancer vaccine developed by Inovio Pharmaceuticals. Its target is PSMA (the sponsor names WT1, PSMA, hTERT). The sponsor states: A combination of three separate DNA plasmids targeting the Wilms tumour gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT), delivered intramuscularly followed by electroporation with the CELLECTRA device to stimulate an anti-tumour immune response. ClinicalTrials.gov describes the intervention as: INO-5401 is a combination of 3 separate DNA plasmids targeting Wilms tumour gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) genes. Starting on Day 0 three milligrams (mg) of. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in glioma & glioblastoma. The largest, NCT03491683, plans to enrol 52 participants (actual) with primary completion expected 2026-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of INO-5401","url":"https://clinicaltrials.gov/search?intr=INO-5401"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":["psma"],"drugs":[],"companies":["inovio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct03491683"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"vaccine","mechanism":"A combination of three separate DNA plasmids targeting the Wilms tumour gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT), delivered intramuscularly followed by electroporation with the CELLECTRA device to stimulate an anti-tumour immune response.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ino-5401/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"},{"id":"wt1","kind":"target","name":"WT1","route":"/targets/wt1/"}],"company":[{"id":"inovio","kind":"company","name":"Inovio Pharmaceuticals","route":"/companies/inovio/"}],"trial":[{"id":"nct03491683","kind":"trial","name":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","route":"/trials/nct03491683/"}]}}